Merck begins construction on $1B Keytruda manufacturing facility in Delaware
Seven weeks after opening a new $1 billion vaccine manufacturing facility in North Carolina, Merck has revealed that it is breaking ground on another $1 billion plant—this one in Wilmington, Delaware, which will produce the company's megablockbuster cancer drug Keytruda.
